For the
treatment of
pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents
For illustrative purposes only.
Select a dilating agent used in RYZUMVI clinical trials to learn more.
Phenylephrine works by binding to the alpha-1 adrenergic receptors on the iris dilator muscle, causing the muscle to contract and pupil to dilate. This duration of activity may last approximately 3-8 hours.3
RYZUMVI, on the other hand, reverses pupil dilation by binding to the alpha-1 adrenergic receptors, preventing phenylephrine from binding, and returns the pupil to its baseline size.1
Tropicamide is a muscarinic antagonist that blocks the responses of the iris sphincter and ciliary muscles to cholinergic stimulation, dilating the pupil and paralysis of the ciliary muscle. The stronger preparation (1%) also paralyzes accommodation. This duration of activity can last ~3-8 hours, and complete recovery may require 24 hours.4-6
RYZUMVI indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.1
Paremyd is a combination eye drop containing hydroxyamphetamine hydrobromide (1%) and tropicamide (0.25%). Hydroxyamphetamine is an indirectly-acting adrenergic agent that works by causing the release of norepinephrine resulting in dilation. Tropicamide is a muscarinic antagonist that blocks the response of the iris sphincter and ciliary muscles to cholinergic stimulation, dilating the pupil and paralysis of the ciliary muscle. Duration of activity may last 6 to 8 hours. In some cases, complete recovery may take up to 24 hours.6-7
RYZUMVI indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.1
RYZUMVI reversed pupil dilation regardless of whether phenylephrine, tropicamide, or Paremyd® (hydroxyamphetamine hydrobromide and tropicamide) was used.1,8,9
Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.
Adverse Reactions
The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).
Please see Full Prescribing Information
References: 1. RYZUMVI (phentolamine ophthalmic solution). Prescribing Information. Ocuphire. 2. Smith PG. Neural regulation of the pupil. Encyclopedia of Neuroscience. 2024. 3. Phenylephrine. Prescribing Information. Akorn, Inc. 2015. 4. Jewell R. Tropicamide. xPharm: The comprehensive Pharmacology Reference. 2007;1-5. 5. Tropicamide. Prescribing Information. Alcon Laboratories, Inc. 2022. 6. Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology. 12th Edition. McGraw Hill Lange; 2012. 7. Paremyd. Prescribing Information. Akorn, Inc. 2001. 8. Viatris. Data on file. OPI-NYXRM-301 (MIRA-2) Clinical Study Report. October 25, 2021. 9. Viatris. Data on file. OPI-NYXRM-302 (MIRA-3) Clinical Study Report. August 10, 2022.
